PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.
Recent Highlights
Total revenue of $24.4 million for the first quarter of 2023, an increase of 72% compared to the prior year period in 2022
U.S. handpiece and consumables revenue of $11.8 million for the first quarter of 2023, an increase of 165% compared to the prior year period in 2022
U.S. system and rental revenue of $8.8 million for the first quarter of 2023, an increase of 13% compared to the prior year period in 2022
Increased fiscal year 2023 total revenue guidance to $128.0 million
Received positive coverage policy decision from United Healthcare, effective June 1, 2023
Signed national sales contract with largest U.S. IDN on April 1, 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.